A 32-year-old woman with biopsy-proven SLE (Class III lupus nephritis) has completed 6 months of induction therapy with mycophenolate mofetil (MMF) 3 g/day and prednisolone 0.5 mg/kg/day. Repeat urinalysis shows persistent proteinuria (1.5 g/24 h) and active urinary sediment. Serum creatinine is stable at 1.2 mg/dL. What is the most appropriate next step?

Explanation

## Clinical Context This patient has a **partial response** to induction therapy — persistent proteinuria (1.5 g/24 h) and active urinary sediment after 6 months of MMF 3 g/day + prednisolone, but with **stable serum creatinine (1.2 mg/dL)**. This is a critical distinction: partial response ≠ treatment failure requiring induction switch. ## Defining Response at 6 Months (ACR/EULAR 2019 Guidelines) | Response Category | Proteinuria | Urinary Sediment | Serum Creatinine | |---|---|---|---| | **Complete Remission** | <0.3 g/24 h | Inactive | Stable/improved | | **Partial Remission** | 0.3–3 g/24 h | May be active | Stable | | **No Response / Refractory** | >3 g/24 h OR rising Cr | Active | Rising | This patient fits **partial response** — proteinuria 1.5 g/24 h (within 0.3–3 g range), stable creatinine. This is NOT the same as refractory disease. ## Why Option C is Correct For **partial responders** at 6 months, the recommended approach per EULAR/ERA-EDTA guidelines is: - **Add adjunctive therapy**: tacrolimus (calcineurin inhibitor, target trough 5–10 ng/mL) is particularly effective for proteinuria reduction in lupus nephritis; azathioprine can be added for maintenance bridging. - **Consider rituximab** if no improvement in 3 months — B-cell depletion is increasingly used in refractory/partial-response lupus nephritis (supported by LUNAR trial data and real-world cohorts). ## Why Option B is Incorrect **Cyclophosphamide induction** is reserved for: 1. Severe, rapidly progressive lupus nephritis (Class IV with crescents, rising creatinine) 2. Failure of BOTH MMF AND rituximab 3. Life-threatening extrarenal manifestations Switching to cyclophosphamide in a patient with **stable renal function and partial response** is premature and exposes the patient to unnecessary toxicity (gonadotoxicity, hemorrhagic cystitis, infection risk, secondary malignancy). The verifier's suggestion to switch to cyclophosphamide conflates "partial response" with "refractory disease." ## Why Options A and D are Incorrect - **Option A**: Waiting another 6 months without escalation is inappropriate — active urinary sediment at 6 months mandates intervention. - **Option D**: Switching MMF to mycophenolate sodium (enteric-coated) is a formulation change, not a therapeutic escalation; it does not address treatment inadequacy. ## Key Point: **The distinction between partial response and refractory disease determines the next step.** Partial responders (stable creatinine, proteinuria 0.3–3 g/24 h) should receive adjunctive therapy (tacrolimus or rituximab) before escalating to cyclophosphamide. Cyclophosphamide is reserved for true refractory disease or rapidly progressive nephritis. *(EULAR Recommendations for SLE Management, 2019; Fanouriakis et al., Ann Rheum Dis 2019)* ## Clinical Pearl: - **Tacrolimus** added to MMF ("multitarget therapy") has shown superior complete remission rates vs. MMF alone in Asian cohorts (Liu et al., JASN 2015). - **Rituximab** (anti-CD20) depletes B cells and is effective in refractory lupus nephritis; LUNAR trial showed trends toward improved renal response. - **Cyclophosphamide** (NIH protocol or Euro-Lupus) is NOT the next step for partial responders with stable creatinine — it is reserved for aggressive or MMF/rituximab-refractory disease. ## Mnemonic: TRIM for Partial-Response Lupus Nephritis **T**acrolimus adjunct → **R**ituximab if no response → **I**ncrease monitoring → **M**aintain MMF — before considering cyclophosphamide switch.